Dolby Laboratories (DLB) | Financial Analysis & Statements
Dolby Laboratories Inc. Mid-cap Industrials
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
346.7M
Gross Profit
303.5M
87.54%
Operating Income
72.6M
20.95%
Net Income
53.7M
15.48%
EPS (Diluted)
$0.55
Balance Sheet Metrics
Total Assets
3.2B
Total Liabilities
589.3M
Shareholders Equity
2.6B
Debt to Equity
0.23
Cash Flow Metrics
Operating Cash Flow
18.9M
Free Cash Flow
49.4M
Revenue & Profitability Trend
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Dolby Laboratories Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 1.3B | 1.3B | 1.3B | 1.3B | 1.3B |
| Cost of Goods Sold | 160.1M | 140.5M | 152.6M | 141.4M | 130.0M |
| Gross Profit | 1.2B | 1.1B | 1.1B | 1.1B | 1.2B |
| Gross Margin % | 88.1% | 89.0% | 88.3% | 88.7% | 89.9% |
| Operating Expenses | |||||
| Research & Development | 261.8M | 263.7M | 271.5M | 261.2M | 253.6M |
| Selling, General & Administrative | 647.2M | 604.9M | 612.8M | 634.0M | 556.8M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 909.0M | 868.5M | 884.4M | 895.2M | 810.5M |
| Operating Income | 280.0M | 264.7M | 262.8M | 217.2M | 340.8M |
| Operating Margin % | 20.8% | 20.8% | 20.2% | 17.3% | 26.6% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | 6.6M | 3.5M |
| Interest Expense | - | - | - | 394.0K | 479.0K |
| Other Non-Operating Income | 8.1M | 13.7M | -40.8M | -8.1M | 10.7M |
| Pre-tax Income | 303.5M | 312.5M | 250.1M | 215.3M | 354.5M |
| Income Tax | 47.0M | 48.2M | 48.4M | 31.4M | 36.7M |
| Effective Tax Rate % | 15.5% | 15.4% | 19.4% | 14.6% | 10.3% |
| Net Income | 256.5M | 264.3M | 201.6M | 183.9M | 317.8M |
| Net Margin % | 19.0% | 20.8% | 15.5% | 14.7% | 24.8% |
| Key Metrics | |||||
| EBITDA | 393.6M | 358.4M | 405.4M | 331.5M | 449.9M |
| EPS (Basic) | $2.66 | $2.74 | $2.10 | $1.84 | $3.07 |
| EPS (Diluted) | $2.62 | $2.69 | $2.05 | $1.81 | $2.97 |
| Basic Shares Outstanding | 95868000 | 95544000 | 95771000 | 99990000 | 101190000 |
| Diluted Shares Outstanding | 95868000 | 95544000 | 95771000 | 99990000 | 101190000 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Dolby Laboratories Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 701.9M | 482.0M | 745.4M | 620.1M | 1.2B |
| Short-term Investments | 703.0K | 0 | 139.1M | 189.2M | 38.8M |
| Accounts Receivable | 331.1M | 315.5M | 262.2M | 243.6M | 232.6M |
| Inventory | 30.4M | 33.7M | 35.6M | 23.5M | 11.0M |
| Other Current Assets | 23.9M | 40.2M | 26.3M | 23.2M | 32.8M |
| Total Current Assets | 1.4B | 1.2B | 1.5B | 1.3B | 1.8B |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 267.6M | 283.4M | 252.1M | 229.2M | 214.1M |
| Goodwill | 1.5B | 1.5B | 984.2M | 842.6M | 804.3M |
| Intangible Assets | 397.1M | 434.5M | 167.4M | 112.3M | 122.9M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 328.5M | 340.4M | 296.5M | 238.7M | 217.3M |
| Total Non-Current Assets | 1.8B | 1.9B | 1.5B | 1.4B | 1.3B |
| Total Assets | 3.2B | 3.1B | 3.0B | 2.7B | 3.1B |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 17.8M | 17.4M | 20.9M | 14.2M | 17.8M |
| Short-term Debt | 10.4M | 12.2M | 13.6M | 13.3M | 15.4M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | - | - | - | - | - |
| Total Current Liabilities | 437.8M | 417.8M | 422.2M | 277.5M | 315.7M |
| Non-Current Liabilities | |||||
| Long-term Debt | 28.5M | 34.8M | 37.0M | 37.7M | 56.7M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 48.4M | 52.6M | 29.6M | 12.2M | 15.4M |
| Total Non-Current Liabilities | 158.0M | 205.2M | 185.4M | 161.0M | 185.7M |
| Total Liabilities | 595.8M | 623.0M | 607.6M | 438.5M | 501.5M |
| Equity | |||||
| Common Stock | 94.0K | 94.0K | 94.0K | 94.0K | 100.0K |
| Retained Earnings | 2.6B | 2.5B | 2.4B | 2.3B | 2.6B |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 2.6B | 2.5B | 2.4B | 2.3B | 2.6B |
| Key Metrics | |||||
| Total Debt | 38.9M | 47.0M | 50.6M | 50.9M | 72.1M |
| Working Capital | 950.5M | 776.6M | 1.1B | 1.0B | 1.4B |
Balance Sheet Composition
Dolby Laboratories Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 256.5M | 264.3M | 201.6M | 183.9M | 317.8M |
| Depreciation & Amortization | 98.6M | 87.3M | 95.5M | 103.6M | 112.8M |
| Stock-Based Compensation | 128.5M | 119.8M | 118.5M | 114.9M | 99.7M |
| Working Capital Changes | -55.1M | -82.1M | 6.4M | -31.5M | -41.8M |
| Operating Cash Flow | 432.4M | 356.9M | 401.0M | 336.5M | 446.0M |
| Investing Activities | |||||
| Capital Expenditures | -36.3M | -30.0M | -30.3M | -47.9M | -54.5M |
| Acquisitions | -1.4M | -487.9M | 25.7M | -38.2M | -4.5M |
| Investment Purchases | -75.0K | -160.2M | -173.0M | -316.3M | -67.1M |
| Investment Sales | 15.9M | 391.8M | 231.8M | 118.0M | 64.8M |
| Investing Cash Flow | -5.0M | -286.3M | 54.2M | -284.4M | -44.9M |
| Financing Activities | |||||
| Share Repurchases | -162.2M | -199.1M | -180.4M | -566.9M | -278.1M |
| Dividends Paid | -126.6M | -114.6M | -103.4M | -100.1M | -89.2M |
| Debt Issuance | - | - | - | - | - |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | -247.2M | -287.8M | -236.8M | -610.6M | -252.5M |
| Free Cash Flow | 430.3M | 297.2M | 336.7M | 259.1M | 393.3M |
| Net Change in Cash | 180.2M | -217.2M | 218.4M | -558.5M | 148.6M |
Cash Flow Trend
Dolby Laboratories Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
26.28
Forward P/E
14.01
Price to Book
2.39
Price to Sales
4.63
PEG Ratio
-1.24
Profitability Ratios
Profit Margin
17.97%
Operating Margin
20.95%
Return on Equity
9.46%
Return on Assets
5.26%
Financial Health
Current Ratio
3.18
Debt to Equity
1.56
Beta
0.86
Per Share Data
EPS (TTM)
$2.47
Book Value per Share
$27.15
Revenue per Share
$13.97
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| DLB | 6.0B | 26.28 | 2.39 | 9.46% | 17.97% | 1.56 |
| Cintas | 71.1B | 36.93 | 14.59 | 41.30% | 17.57% | 60.94 |
| Copart | 32.8B | 21.22 | 3.32 | 17.13% | 33.76% | 0.98 |
| Amentum Holdings | 6.6B | 69.48 | 1.49 | 1.78% | 0.69% | 84.41 |
| UniFirst | 4.7B | 35.44 | 2.17 | 6.27% | 5.49% | 3.66 |
| Azz | 4.4B | 12.82 | 3.09 | 27.38% | 19.89% | 43.11 |
Financial data is updated regularly. All figures are in the company's reporting currency.





